1. B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY. (5th April 2022) Authors: Rodriguez-Otero, P; Dholaria, B; Askari, E; Reece, D; van de Donk, N; Chari, A; Goldschmidt, H; Krishnan, A; Martin, T; Mateos, M; Morillo, D; Rodriguez, C; Rosinol, L; San-Miguel, J; Balari, A; Wäsch, R; Weisel, K; Verona, R; Lin, S; Prior, T Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL. (5th April 2022) Authors: Dimopoulos, MA; Oriol, A; Nahi, H; San-Miguel, J; Bahlis, NJ; Usmani, SZ; Rabin, N; Orlowski, RZ; Suzuki, K; Plesner, T; Yoon, SS; Ben Yehuda, D; Richardson, PG; Goldschmidt, H; Reece, D; Ahmadi, T; Qin, X; Garvin Mayo, W; Gai, X; Carey, J Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (5th April 2022) Authors: Popat, R; Usmani, S; Garfall, A; van de Donk, N; Nahi, H; San-Miguel, J; Oriol, A; Nooka, A; Martin, T; Rosinol, L; Chari, A; Karlin, L; Benboubker, L; Mateos, M; Bahlis, N; Moreau, P; Besemer, B; Martínez-López, J; Sidana, S; Pei, L Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL. (5th April 2022) Authors: Rodríguez-Otero, P; Shah, N; Munshi, N; Berdeja, J; Jagannath, S; Finney, O; Martin, N; Agarwal, A; Rowe, E; Campbell, T; San-Miguel, J Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY. (5th April 2022) Authors: Rodríguez-Otero, P; San-Miguel, J; Anderson, LD; Lonial, S; Truppel-Hartmann, A; Sanford, J; Rowe, E; Campbell, TB; Munshi, N Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗